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Abstract
Human multidrug and toxin extrusion member 1, MATE1 (SLC47A1), plays an important role in
the renal and biliary excretion of endogenous and exogenous organic cations including many
therapeutic drugs. In this study, we characterized the transcriptional effects of five polymorphic
variants and six common haplotypes in the basal promoter region of MATE1 that were identified in
272 DNA samples from ethnically diverse U.S. populations. We measured luciferase activities of
the six common promoter haplotypes of MATE1 using in vitro and in vivo reporter assays. Haplotypes
that contain the most common variant (mean allele frequency in four ethnics: 0.322), g.−66T>C,
showed a significant decrease in reporter activities compared to the reference. Two transcription
factors, AP-1 and AP-2rep, were predicted to bind to the promoter in the region of g.−66T>C. Results
from electrophoretic mobility shift assays showed that the g.−66T allele, exhibited greater binding
to AP-1 than the g.−66C allele. AP-2rep inhibited the binding of AP-1 to the MATE1 basal promoter
region, and the effect was considerably greater for the g.−66T>C. These data suggest that the reduced
transcriptional activity of g.−66T>C results from a reduction in the binding potency of the
transcriptional activator, AP-1, and an enhanced binding potency of the repressor, AP-2rep to the
MATE1 basal promoter region. Consistent with the reporter assays, MATE1 mRNA expression levels
were significantly lower in kidney samples from individuals who were homozygous or heterozygous
for g.−66T>C in comparison to samples from individuals who were homozygous for the g.−66T
allele. Our study suggests that the rate of transcription of MATE1 is regulated by AP-1 and AP-2rep
and that a common promoter variant, g.−66T>C may affect the expression level of MATE1 in human
kidney, and ultimately result in variation in drug disposition and response.
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Introduction
The liver and kidney are the major organs responsible for the elimination of drugs and other
xenobiotics from the body [1]. Transporters localized to the sinusoidal membrane of the
hepatocyte, take up drugs from the portal blood into the hepatocyte. Subsequently, the drugs
can be transported back into the blood or excreted into the bile in their original chemical forms
or as metabolic products [2]. Human multidrug and toxin extrusion member 1 (MATE1,
SLC47A1, or also known as H+/organic cation antiporter member), is present on the canalicular
membrane of the hepatocyte and appears to work in concert with organic cation transporter 1
(OCT1) to mediate the biliary excretion of many cationic drugs and their metabolites [3].
Previous studies have demonstrated that various drugs and environmental toxins including
cimetidine, metformin, and paraquat are substrates of MATE1 [4,5]. In the kidney, MATE1 is
highly expressed on the apical membrane of the proximal tubule and may work with the
basolateral membrane transporter, human organic cation transporter 2 (OCT2), in the renal
secretion of organic cations [3,6]. In addition to the liver and kidney, other tissues that express
MATE1 in high abundance include the adrenal gland, testis, and skeletal muscle [7].
Recently, we identified four synonymous and six non-synonymous coding region variants of
MATE1 in DNA samples from a large ethnically diverse cohort of healthy volunteers (68
individuals from each population: European Americans, African Americans, Chinese
Americans and Mexican Americans). Using a mammalian expression system, we observed that
several singleton non-synonymous single nucleotide polymorphisms (SNPs) of MATE1
showed significant loss of function for all substrates tested and that several common non-
synonymous SNPs (> 5% minor allele frequency) showed selectively reduced transport for
some substrates [8]. These findings suggested that genetic variants in MATE1 may alter drug
disposition and ultimately affect clinical drug response.
Genetic variation in the promoter region of MATE1 has also been described. In particular,
Kajiwara M, et al [9] identified a SNP, g.−32G>A (from translational start site, allele
frequency: 3.7%) in DNA samples from a Japanese population within a specificity protein 1
(Sp-1) binding site of the proximal promoter region of MATE1. This polymorphism had
reduced expression activity in reporter assays [9].
The goal of the current study was to identify and functionally characterize basal promoter
region polymorphisms in MATE1. We screened DNA samples from a large ethnically diverse
U.S. population for variants in the basal promoter of MATE1 and investigated the function of
the variants using both in vivo and in vitro reporter assays. Our study provides information
about the mechanisms responsible for the transcriptional regulation of MATE1 and identifies
a functionally important genetic polymorphism that may contribute to variation in the
expression level of this transporter.
Materials and Methods
Genetic analysis
Genomic DNA samples were collected from unrelated healthy individuals from four major
ethnic groups (68 each from European Americans, African Americans, Chinese Americans,
and Mexican Americans) as a part of the Study Of PHarmacogenetics In Ethnically-diverse
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populations (SOPHIE). To identify polymorphisms in the promoter region of MATE1, a
polymerase chain reaction (PCR) fragment (−636 to +114 bp from the translational start site)
was amplified and directly sequenced by an automated genetic analyzer using the primers listed
in Table 3. Haplotype assembly was performed using the Haploview 4.1 program (Broad
Institute, Cambridge, MA, USA), based on a standard expectation-maximization algorithm
[10], to reconstruct individual haplotypes from population genotype data. Nucleotide location
number was assigned from the translational start site according to the MATE1 mRNA sequence
(GenBank accession number; NM_018242). We followed the nomenclature system that was
recommended by Antonarakis SE, et al [11,12].
Construction of MATE1 variants in the promoter region
To construct the reporter plasmids containing the MATE1 promoter region, 559 bp of the
MATE1 gene was amplified from genomic DNA samples from individuals having each
haplotype listed in Table 2. The amplified products were inserted into pCR2.1-TOPO vectors
(Invitrogen Corporation) and were directly sequenced. The second PCR was performed using
the primers containing the restriction endonuclease sites, NheI and HindIII (Table 3). The
amplified 223 bp products were inserted into the pGL4.11b [luc2] vectors (Promega
Corporation) and DNA sequences were confirmed by direct sequencing.
Measurement of MATE1 promoter activity in vitro
The reporter plasmids containing the reference or variants of MATE1 were transfected into
HCT-116 (human colon carcinoma), ACHN (human kidney adenocarcinoma), HepG2 (human
liver, carcinoma), and HeLa (human uterus carcinoma) cell lines using Lipofectamine LTX
and Plus reagents (Invitrogen) according to the manufacturers’ protocol. HCT-116 cells were
cultured in high glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS) while ACHN cells were cultured in Roswell Park Memorial
Institute (RPMI) medium 1640 supplemented with 10% FBS. HepG2 and HeLa cells were
cultured in minimum essential medium (MEM) supplemented with 10% FBS. Thirty hours
after transfection, the reporter activity was measured using the Dual-luciferase® reporter assay
system (Promega) according to the manufacturers’ protocol and quantified using the Glomax
96-well plate luminometer (Promega). The firefly luciferase to renilla luciferase ratios were
determined and expressed as relative luciferase activity. To examine the effect of AP-2rep on
the promoter activity of MATE1, reference or variant reporter plasmids were co-transfected
with increasing amounts of AP-2rep-pcDNA5-FRT vector (3 ng to 50 ng). The AP-2rep gene
(BC_019680) was amplified from human kidney cDNA by PCR using primers listed in Table
3 and inserted into pcDNA5-FRT vector. The amount of transfected plasmid was equalized by
adding pcDNA5-FRT vector.
Measurement of MATE1 promoter activity in vivo
For the in vivo functional assay, hydrodynamic tail vein injection experiments were performed
on at least 10 mice per construct using the TransIT® In Vivo gene delivery system (Mirus Bio
Corporation) following the manufacturers’ protocol. Briefly, 10 µg of pGL4.11b [luc2] vector
containing either no promoter or the MATE1 promoter constructs (reference haplotype H1 or
variant haplotype H2) alongside 2 µg of pGL4.74 [hRluc/TK] vector, to correct for injection
efficiency, was injected into the tail vein of CD1 mice (Charles River) weighing 22–24 g. After
24 hours, animals were euthanized, livers were dissected and homogenized in passive lysis
buffer (Promega) followed by centrifugation for 30 min at 14,000 rpm. Firefly luciferase and
renilla luciferase activity in the supernatant (diluted 1:20 with buffer) were measured six times
for each liver using the Dual-luciferase® reporter assay system, and quantified using the
Synergy 2 (BioTek Instruments, Inc.). The firefly luciferase to renilla luciferase ratios were
determined and expressed as relative luciferase activity.
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Electrophoretic mobility shift assay (EMSA) of MATE1
Nuclear protein extracts were obtained from naïve HCT-116 cells, from HCT-116 cells treated
with 10 ng/ml of TNF-α, or from HCT-116 cells transfected with the AP-2rep-pcDNA-FRT
plasmid. The nuclear protein extraction procedure was performed according to a previously
described method with some modifications [13]. Oligonucleotides used in the EMSA are listed
in Table 3. The method used for the EMSA has been described previously [13]. Nuclear protein
extracts (20 or 30 µg) were incubated with 2 µl of 32P-labeled oligonucleotide (1×105 counts/
min or 2×105 counts/min or 4×105 counts/min) in a buffer containing 7% glycerol, 10 mM
HEPES (pH 7.9), 1 mM EDTA (pH 8.0), 1 mM DTT, and 0.2 µg poly(deoxyinosinate-
deoxycytidylate) in a final volume of 20 µl for 30 minutes at room temperature. The reaction
mixtures were loaded on 6% nondenaturing polyacrylamide gel and electrophoresed for 2 hours
at 200 V. The dried gel was exposed to Kodak XR-5 film (Eastman Kodak Corporation) on an
intensifying screen for 10–24 hours at room temperature or −80°C. For the shift assay, 2 µl of
phospho-c-jun (9164, Cell Signaling Technology Inc.) or 1 µl of c-fos (sc-253X, Santa Cruz
Biotechnology Inc.) antibody was incubated with the nuclear extract for 20 minutes at room
temperature prior to the binding reaction. The intensity of each band on the film was measured
using Scion image (Scion Corporation).
Quantification of MATE1 gene expression using quantitative real-time RT-PCR
Using TRIZOL reagent (Invitrogen), total RNA was isolated from 38 surgical sections of
human kidney (23 normal renal cortex adjacent to tumor section of renal cell carcinoma and
15 renal cortex from tissues of individuals with various disease diagnoses) and 34 human liver
samples were normal postmortem tissue. The age of the donors ranges from 36 to 83 years.
The clinical diagnoses of the kidney donors were renal cell carcinoma, chronic obstructive
pulmonary disease, ischemic heart disease or chronic heart failure; whereas the clinical
diagnoses of the donors of the post-mortem liver samples were pneumonia, ischemic heart
disease and Non-Hodgkin Lymphoma. These samples were purchased from Asterand plc and
Capital Biosciences. All samples collected were stored frozen at −80 °C from collection until
processing for RNA and DNA. These samples were all from individual with European ancestry
background. Single strand cDNAs were synthesized using a Superscript III first-strand
synthesis system for RT-PCR (Invitrogen). Quantitative real-time RT-PCR was performed
using a 7500 Fast RT-PCR system (Applied Biosystems) with Taqman gene expression assays.
The total reaction volume in each well was 10 µl, including 50 ng of cDNA, 0.5 µl of 20-fold
primers (Hs00217320_m1, Applied Biosystems), and 5 µl of 2-fold Taqman Fast Universal
PCR Master Mix (Applied Biosystems). The RT-PCR was started with 95°C for 20 seconds,
and continued with 40 cycles of 95°for 3 seconds and 60°C for 30 seconds. Relative quantitative
analysis was performed with 7500 Fast System SDS software 1.4 and the expression of
endogenous human GAPDH gene was used as an internal standard to correct for the amount
of added cDNA. The genomic DNA of these tissue samples were isolated, and a 559 bp PCR
fragment was amplified using the MATE1 promoter cloning primers and directly sequenced
by an automated genetic analyzer.
RNA mediated interference
Validated small interfering RNA (siRNA) for c-jun (VHS40918, Invitrogen) was reverse-
transfected into HCT-116 cells using Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturers’ protocol. Stealth RNAi negative control high GC (Invitrogen) was used as a
negative control. Forty-two hours after transfection, the reporter plasmids containing the
reference or variant MATE1 were transfected into the cells using Lipofectamine LTX and Plus
reagents according to the manufacturer’s protocol. Thirty hours after transfection, the reporter
activity was measured using the Dual-luciferase® reporter assay system according to the
manufacturer’s protocol and quantified using the Glomax 96-well plate luminometer. Firefly
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luciferase to renilla luciferase ratios were determined and expressed as relative luciferase
activity.
Statistical analysis
Results of luciferase assays presented were derived from two or three independent experiments
and were shown as the mean ± SD. All P values except for those obtained in the in vivo
luciferase assays were calculated using Dunnett's multiple comparison test. The P value for
the in vivo luciferase assay was calculated using Student’s t test. P values less than 0.05 were
considered statistically significant. A D’Agostino and Pearson omnibus normality test
(GraphPad Prism 5) was used to determine whether the expression levels of MATE1 in kidney
and in liver were normally distributed.
Results
Genetic polymorphisms of MATE1 in the promoter region
We identified eight variants in the promoter region of MATE1 in 272 DNA samples from
ethnically diverse U.S. populations. Five of the variants were polymorphic (minor allele
frequency > 1%) in at least one of the four ethnic groups (Table 1). The g.−66T>C was present
in all four populations and the frequency of this variant was the highest in all ethnic groups.
In our study, we did not observe the g.−32G>A (from transcriptional start site) polymorphism
identified previously in a Japanese population [9]. Table 2 shows the frequency distributions
of the common haplotypes in the MATE1 promoter region that occurred at minor allele
frequencies > 1% in at least one of the four ethnic groups. Haplotype 1, which consists of all
major alleles, showed the highest frequency, followed by Haplotype 2, which contains g.
−66T>C.
Promoter activity of MATE1 variants in vitro
To characterize the functional effects of the promoter variants, we constructed MATE1-
pGL4.11b [luc2] reporter plasmids that included the essential region for the basal
transcriptional activity of MATE1 [9]. The reporter assay was performed 30 hours after
transfection of the reporter plasmids into four different cell lines: HCT-116, ACHN, HepG2,
and HeLa. Haplotype 1 was used as a reference for the functional analysis. The promoter
activities of Haplotypes 2, 3, and 4, all of which contained the g.−66T>C variant showed
decreased reporter gene expression by 16–44% compared to that of the reference in all cell
lines except for HepG2 cells in which haplotype 3 and 4 showed similar activity to the reference
haplotype 1 (Fig. 1). Haplotype 5, which contains variants, g.−53C>G, g.−44C>T, and g.−27_
−26ins, showed 13–110% increased promoter activity, compared to that of the reference
haplotype in all cell lines. These results appear to be explained by the presence of the variants
g.−44C>T, and g.−27_−26ins, which tended to have higher reporter activities in these cell
lines. There was no individual having a haplotype that contained only the variants g.−44C>T,
and g.−27_−26ins in this study. Interestingly, the promoter activity of Haplotype 6, which
contained both the reduced function variant, g.−66T>C, and the increased function variants,
g.−44C>T and g.−27_−26ins, was comparable to that of the reference haplotype in HCT-116
and ACHN cell lines (Fig. 1).
Promoter activity of a MATE1 variant in vivo
To confirm the findings obtained in the reporter assays in cells with respect to g.−66T>C, we
measured the promoter activity of MATE1 in vivo in mouse liver. We took advantage of the
hydrodynamic tail vein injection technique in order to express our reporter assay constructs in
the mouse liver [14]. Consistent with our in vitro results, we observed that the construct
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containing the variant g.−66T>C showed a significant decrease in luciferase activity in
comparison to the reference allele (Fig. 2).
Effect of variant, g.−66T>C on the binding affinity of AP-1 and AP-2rep within the MATE1
promoter region
Due to the high frequency and reduced function of the g.−66T>C, we investigated the
mechanisms by which this variant may cause a reduction in transcriptional activity. First, we
identified the transcription factors that could bind to the basal promoter region of MATE1 in
the vicinity of g.−66T>C. Two different transcription factors, namely activating protein-1
(AP-1) and activating protein-2repressor (AP-2rep) were identified using TFSearch 3.1 (Real-
World Company Partnership) and the Delta-Match query tool (developed by Dr. David W.
Williamson (personal communication)). AP-1 is a strong oncogene that mediates tumor cell
invasion and AP-2rep belongs to a family of Krüppel-like factor (KLF) and works as a repressor
of AP-2α [15,16]. TFSearch 3.1 predicted that AP-1 would have a higher binding affinity to
the g.−66T allele, than the g.−66C allele, whereas the Delta-Match query tool predicted that
the g.−66C allele, would bind with a higher affinity to AP-2rep than the g.−66T allele. These
predictions, if validated, would explain the reduced transcriptional activity of the variant, i.e.,
in the presence of the variant, AP-1 would activate transcription less potently whereas AP-2rep
would repress transcription more potently.
To functionally validate these predictions, we first determined whether AP-1 could bind to the
promoter region containing the g.−66T>C site through electrophoretic mobility shift assay
(EMSA). Oligonucleotides (2×105 counts/min, reference g.−66T: lanes 1–4 and 6; variant g.
−66C: lane 5, Fig. 3 (a)) were incubated with nuclear protein extracts (20 µg) obtained from
HCT-116 (lanes 1–5) or tumor necrosis factor-α (TNF-α) treated HCT-116 cells (lane 6),
because TNF-α is known to induce the expression of AP-1 [17]. Both reference and variant
probes formed DNA-protein complexes, although the intensity of the complex with the variant
probe was decreased by 12%, compared to the reference (lanes 4–5, Fig. 3 (a)). AP-1 is found
either as a homodimer of the Jun family or in heterodimers between members of the Fos and
Jun families [16]. The presence of the supershift with antibodies against phosphorylated c-jun
and c-fos confirmed that AP-1 was present in the complex (lanes 2–3, Fig. 3 (a)). Consistent
with a previous study indicating that TNF-α could induce the expression of AP-1, we confirmed
that the binding of the reference probe with AP-1 was increased by 17% after exposure to TNF-
α (lane 6, Fig. 3 (a)) [17]. To support the result from the supershift assay, we performed a
competition assay using the AP-1 consensus probe (Fig. 3 (b) and (c)) [15]. The AP-1 consensus
probes (1×105 counts/min, lanes 1–4, Fig. 3 (b)) or MATE1 reference probes (1×105 counts/
min, lanes 5–11, Fig. 3 (b)) were incubated with nuclear protein extracts (20 µg) obtained from
HCT-116 cells. In the competition assay, various concentrations of unlabelled AP-1 consensus
oligonucleotides competed with AP-1 consensus (lanes 2–4, Fig. 3 (b)) or MATE1 reference
probes (lanes 6–8, Fig. 3 (b)) in a dose dependent manner. Similarly, the unlabelled MATE1
reference oligonucleotides competed in a dose-dependent manner with the labeled MATE1
reference probe as shown in lanes 9–11 (Fig. 3 (b)). The binding affinity between reference,
g.−66T and variant, g.−66C for AP-1 consensus sequence were examined in a competition
assay using AP-1 consensus probes (1×105 counts/min) with various concentrations of the
unlabeled MATE1 reference (lanes 2–5, Fig. 3 (c)) or variant (lanes 6–9, Fig. 3 (c))
oligonucleotides and HCT-116 nuclear protein extracts (20 µg). The reference oligonucleotide
appeared to be a stronger competitor than the variant, suggesting that the MATE1 reference,
g.−66T has a higher affinity for the AP-1 consensus than the MATE1 variant, g.−66C.
Next, we conducted EMSAs with nuclear protein extracts obtained from AP-2rep-over-
expressed HCT-116 cells (Fig. 4). The reference probes (2×105 counts/min) were incubated
with nuclear protein extracts (20 µg) obtained from HCT-116 (lane 1, Fig. 4 (a)) or AP-2rep-
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overexpressed HCT-116 cells (lane 2, Fig. 4 (a)). We found that the intensity of DNA-protein
complex was much weaker in nuclear protein extracts from AP-2rep-over-expressed HCT-116
cells, compared to extracts from control HCT-116 cells. We hypothesized that AP-2rep can
inhibit the binding of AP-1 to the promoter region of MATE1. The DNA-protein complexes
were supershifted with phosphorylated c-jun and c-fos antibodies indicating that these bands
are complexes of DNA with AP-1 (lanes 2–3, Fig. 4 (b)). We also examined the inhibitory
effect of AP-2rep on the binding of DNA with AP-1 through EMSA using the variant probe
(Fig. 4 (c)). Oligonucleotides (4×105 counts/min, reference g.−66T: lanes 1, 3–6, variant g.
−66C: lane 2, Fig. 4 (c)) were incubated with nuclear protein extracts (30 µg) obtained from
AP-2rep-over-expressed HCT-116 cells. The intensity of DNA-protein complex was much
weaker in lane 2, in which the variant probe was used, compared to lane 1, which was probed
with the reference probe. These data suggest that the inhibitory effect of AP-2rep on DNA-
AP-1 binding is much stronger in the presence of the variant, g.−66C, compared to the
reference. A dose-dependent competition of DNA-AP-1 binding was observed after addition
of AP-2rep oligonucleotides (lanes 3–6, Fig. 4 (c)) indicating that AP-1 and AP-2rep can bind
competitively to the region of the MATE1 promoter containing variant, g.−66T>C.
Effect of AP-1 or AP-2rep on the MATE1 promoter activity
The effect of AP-1 on the MATE1 promoter activity was examined by using siRNA to
knockdown c-jun. After 42 hours of siRNA transfection to HCT-116, the reference (H1) or
variant (H2) reporter constructs were transfected into the cells. Reporter activities were
determined after 30 hours. Figure 5 (a) showed a significant reduction in luciferase activities
of the H1 (3.4 fold reduced) and H2 (3.5 fold reduced) reporter constructs in the presence of
c-jun siRNA compared to the luciferase activities with the negative control siRNA. This result
suggests that AP-1 works as a transcription factor that binds to the MATE1 promoter to regulate
its expression. The effect of AP-2rep on the promoter activity of MATE1 was examined by
conducting a luciferase assay after over-expression of AP-2rep transcription factor. To examine
the effect of AP-2rep on the promoter activity of MATE1, reference (H1) or variant (H2)
reporter constructs with increasing amounts of plasmids containing AP-2rep were co-
transfected in HCT-116. We observed that AP-2rep produced a dose-dependent repression of
the MATE1 promoter activity (Fig. 5 (b)).
Effect of g.−66T>C variant on MATE1 expression in human kidney samples
MATE1 expression levels in human kidney samples, determined by a quantitative real-time
RT-PCR, was associated with the g.−66T>C genotype. In particular, MATE1 expression in the
samples with the T/C (n=21) or C/C (n=5) genotypes were significantly lower (34%), compared
to that of samples with the T/T genotype (n=12) (Fig. 6). The MATE1 gene expression in kidney
tissue was normally distributed. This was tested based on D’Agostino and Pearson omnibus
normality test, which demonstrated that the distribution was not significantly different from
normality (P = 0.4734).
Discussion
MATE1 is highly expressed on the apical membrane of the hepatocytes and renal proximal
tubule cells, and mediates the transport of a broad array of drugs [4]. Functional changes in the
activity or expression level of MATE1 caused by genetic variants in the coding or non-coding
region of this transporter could result in changes in the levels of drugs substrates for the
transporter. For example, reduction in the expression level of Mate1 in rats has been associated
with reduced tubular secretion and high blood levels of the anti-ulcer drug, cimetidine [18].
This study was conducted to identify and functionally characterize genetic variants in the
proximal promoter region of MATE1. By screening a large number of samples, we identified
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five variants that are polymorphic in four major ethnic groups. Recently Kajiwara M, et al
[9] described a variant, g.−32G>A, in the MATE1 promoter region that showed markedly
decreased promoter activity. Their study indicated that the Sp1 transcription factor has a critical
role in the basal promoter activity of MATE1, and that the variant, g.−32G>A reduced the
binding affinity of Sp1. Though the allelic frequency of g.−32G>A in the Japanese sample was
3.7%, it was not observed in our study, which included DNA samples from 68 individuals with
ancestries in China. Chinese and Japanese share most alleles, but also have alleles that are
population specific. Our results suggest that g.−32G>A may be a variant not shared between
these two closely related populations.
The most common variant in this study, g.−66T>C showed a significant decrease in promoter
activity in reporter assays in four cell lines (Fig. 1) and in mouse liver (Fig. 2). Transcription
factor binding site (TFBS) analyses suggested that two transcription factors could bind to the
region encompassing g.−66T>C and that the binding affinity of these transcription factors was
variant-dependent. In particular, AP-1 would have a higher binding affinity for the g.−66T
allele whereas AP-2rep would have a higher binding affinity for the g.−66C allele.
AP-1 is a strong oncogene that mediates tumor cell invasion. The expression of AP-1 is highly
elevated in many kinds of tumors such as squamous cell carcinoma, colon carcinoma, breast
carcinoma and fibrosarcoma, and it has a critical role in tumor invasion [15]. Previous studies
reported that AP-1 induces the transcription of transporter genes including the human glucose
transporter 1, the sodium dependent glutamate/aspartate transporter, and the sodium dependent
bile acid transporter [19–21]. In some cases, AP-1 may also act as a repressor; it enhances
tumor cell invasion by the repression of genes that function as invasion suppressors. AP-1 is
thought to bind to the DNA sequence, TGAg/cTCA [15]. We observed that MATE1 contains
the sequence, GTACTCA, which is similar to the consensus sequence recognized by AP-1.
The variant g.−66T>C results in the sequence, GTACCCA, which is not as good of a match
as the reference. Therefore we predicted that AP-1 would have binding preference to the
reference DNA sequence as compared to the variant sequence. The results of EMSAs supported
our hypothesis. The intensity of the DNA-AP-1 complex was decreased in the presence of g.
−66T>C (Fig. 3 (a)). From the competition assay, we observed that g.−66T was a stronger
competitor than g.−66C (Fig. 3 (c)), suggesting that g.−66T has a higher affinity for AP-1 than
g.−66C. We also demonstrated that AP-1 regulates MATE1 transcription (Fig. 5 (a)),
establishing that this transcription factor may be important in regulating the expression of this
transporter.
In contrast to AP-1, there are few reports about AP-2rep. AP-2rep belongs to the KLFs family,
which are characterized by three highly conserved classical Cys2/His2 zinc fingers at the C-
terminus. These motifs enable KLFs to bind to related GC- and CACCC-boxes of DNA. The
N-termini of KLFs contain activation or repression domains. To date, a total of 17 KLFs have
been identified. AP-2rep, also known as KLF 12, has a repressor domain (PVDLS motif) at its
N-terminus [22–24]. Schuierer M, et al [24] reported that the interaction of the repressor
domain of AP-2rep with co-repressor, C-terminal binding protein 1 (CtBP1), could result in
the repression of the AP-2α gene that is involved in embryonic development, and malignant
transformation. AP-2rep is thought to bind to the DNA sequence, CAGTGGG [25]. The
MATE1 promoter contains the sequence, CTCACTG, and the complementary sequence,
CAGTGAG, is very similar to the consensus sequence of AP-2rep. The variant, g.−66T>C
results in CAGTGGG, an exact match to the consensus sequence of AP-2rep. We also found
that over-expression of AP-2rep inhibited AP-1 binding to DNA. In particular, AP-2rep had a
stronger inhibitory effect on the binding of AP-1 to the g.−66C allele than on the binding of
AP-1 to the g.−66T allele (Fig. 4 (c)). We performed competition assays using unlabelled
AP-2rep oligonucleotides to confirm that AP-1 and AP-2rep both bind competitively within
the g.−66T>C region (Fig. 4 (c)). We also observed that AP-2rep could act as a repressor of
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MATE1 transcription (Fig. 5 (b)). In the presence of AP-2rep, the luciferase activity was
reduced dramatically in the presence of the reference g.−66T (Fig. 5 (b)). However, in the
presence of the variant g.−66C, the luciferase activity was reduced significantly only by large
amounts of AP-2rep (at 50 ng) (Fig. 5 (b)). This may suggest that AP-2rep binds more avidly
to the variant g.−66C.
Finally we examined the effect of g.−66T>C on MATE1 expression in human kidney.
MATE1 expression levels in T/C or C/C genotype groups were significantly lower than in the
T/T group, which is consistent with our findings in the luciferase in vitro and in vivo assays.
T hese data suggest that g.−66T>C can affect the pharmacokinetics or pharmacodynamics of
drugs that are transported by MATE1 in the body. However, the g.−66T>C was not associated
with lower expression levels in liver samples (data not shown). Although AP-1 is expressed
in both kidney and liver, the g.−66T>C associates with lower MATE1 expression in the kidney
only [26,27]. In contrast, no significant association between the g.−66T>C and MATE1
expression levels in the liver was observed. This may be explained by differences in samples
and sample collection between liver and kidney. In particular, the liver samples, unlike the
kidney samples, consisted of normal, post-mortem tissue. Variation in sample collection times,
in particular time from death to sample collection, could have confounded the observed
MATE1 expression levels in the liver. Kidney samples, on the other hand, were from surgical
resection and collection times and conditions were more standardized. It is also possible that
additional hepatic transcription factors (not present in HepG2 cells or in mouse liver under the
experimental conditions), e.g., inducible nuclear receptors such as Pregnane X receptor (PXR),
which bind to response elements elsewhere in the MATE1 gene may play a role in regulating
the transcription rate of MATE1 in the liver, but not in the kidney.
In conclusion, we identified novel polymorphisms in the promoter region of MATE1. One of
the polymorphisms, g.−66T>C, present at a very high allele frequency in all major ethnic
groups, is associated with a significant reduction in the promoter activity of MATE1 and with
lower expression levels of the transporter in the kidney. The mechanism appeared to be related
to reduced binding of the transcription factor, AP-1, which acts as an activator of transcription,
and to an increased binding of the repressor, AP-2rep, to the region containing the variant g.
−66T>C (Fig. 7). Our data suggest that both transcription factors, AP-1 and AP-2rep, are
involved in the transcriptional regulation of MATE1. Clinical studies examining the effect of
the promoter variant, g.−66T>C, on the pharmacokinetics and pharmacodynamics of MATE1
substrates are ongoing.
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Figure 1.
Luciferase activities in cell lines expressing reporter constructs containing the common
haplotypes of the basal promoter of MATE1. Luciferase activities were measured 30 hours after
transfection of the reporter plasmids into HCT-116 (a), ACHN (b), HepG2 (c), and HeLa
(d) cell lines. The reporter activity of each construct was compared with that of empty vector
(pGL4.11b [luc2]). Data shown represent mean ± SD from triplicate wells in a representative
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experiment. *P < 0.05, **P < 0.01 vs. the reference. Haplotypes (H1–H6) are defined in Tables
2. The variant g.66T>C is contained in H2, H3, H4 and H6. H6 also contains g.−44C>T, present
in H5.
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Figure 2.
The activity of a common promoter region variant, g.−66T>C, of MATE1 in mouse liver.
Activity was assessed after in vivo hydrodynamic injection of reporter constructs into mouse
tail vein. Luciferase activities were measured 24 hours after the injection of the reporter
plasmids into the tail vein of mice (n=10 per each group). The luciferase activity of each
construct was normalized to the luciferase activity measured in liver samples from mice
injected with constructs containing the empty vector (pGL4.11b [luc2]). Data shown represent
mean ± SD from reporter assays from livers of 10 mice. A t-test was used to measure statistical
significance.
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Figure 3.
Electrophoretic mobility shift analysis of MATE1 reference and variant g.−66T>C
oligonucleotides. (a) Oligonucleotides (reference g.−66T: lanes 1–4 and 6; variant g.−66C:
lane 5) were incubated with nuclear protein extracts (20 µg) obtained from HCT-116 or
HCT-116 cells that were pre-incubated with 10 ng/ml of TNF-α for 1 hour (lane 6). The arrow
indicates the position of the DNA protein complex. Supershift experiments were performed
with the antibodies against phosphorylated c-jun (lane 2) and c-fos (lane 3) added separately
to each gel shift reaction. (b) Oligonucleotides (1×105 counts/min, AP-1 consensus: lanes 1–
4, reference g.−66T: lanes 5–11) were incubated with nuclear protein extracts (20 µg) obtained
from HCT-116. Competition reactions were performed using different folds (25 (lanes 2, 6,
9), 250 (lanes 3, 7, 10), 750 (lanes 4, 8, 11)) of molar excess of unlabeled consensus AP-1
(lanes 2–4 and 6–8) or reference g.−66T (lanes 9–11) oligonucleotides. (c) AP-1 consensus
oligonucleotides (1×105 counts/min) were incubated with nuclear protein extracts (20 µg)
obtained from HCT-116. Competition reactions were performed using different folds (50 (lanes
2, 6), 125 (lanes 3, 7), 250 (lanes 4, 8), 500 (lanes 5, 9)) of molar excess of unlabeled reference
g.−66T (lanes 2–5) or variant g.−66C (lanes 6–9) oligonucleotides. The arrow indicates the
position of the DNA protein complex.
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Figure 4.
Effect of AP-2rep on the binding of DNA with AP-1. (a) Reference oligonucleotides (2×105
counts/min) were incubated with nuclear protein extracts (20 µg) obtained from HCT-116 (lane
1) or AP-2rep-over-expressed HCT-116 cells (lane 2). (b) Reference oligonucleotides
(4×105 counts/min) were incubated with nuclear protein extracts (30 µg) obtained from
AP-2rep-overexpressed HCT-116 cells (lanes 1–3). Supershift experiments were performed
with the antibodies against phosphorylated c-jun (lane 2) and c-fos (lane 3) added separately
to each gel shift reaction. (c) Oligonucleotides (4×105 counts/min, reference g.−66T: lane 1
and lanes 3–6, variant g.−66C: lane 2) were incubated with nuclear protein extracts (30 µg)
obtained from AP-2rep-over-expressed HCT-116 cells. Competition reactions were performed
using different folds (25 (lane 3), 50 (lane 4), 100 (lane 5), and 250 (lane 6)) of molar excess
of unlabeled consensus AP-2rep oligonucleotides. The arrow indicates the position of the DNA
protein complex.
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Figure 5.
Effects of AP-1 and AP-2rep on the promoter activity of MATE1. (a) 42 hours after reverse–
transfection using validated small RNA interfering for c-jun, reference or variant reporter
constructs were co-transfected in HCT-116. Thirty hours after the transfection, promoter
activities were measured. The reporter activity of each construct was compared with that of
empty vector (pGL4.11b [luc2]) without small RNA interfering. Significant differences were
observed in promoter activity after knockdown of c-jun. Data shown represent mean ± SD from
triplicate wells in a representative experiment. *P < 0.05, **P < 0.01 vs. the naïve empty vector
promoter activity. (b) Promoter activities were measured 30 hours after the co-transfection of
the reference or variant reporters and various amounts of AP-2rep plasmids into HCT-116 cell.
The reporter activity of each construct was compared with that of empty vector (pGL4.11b
[luc2]). Data shown represent mean ± SD from triplicate wells in a representative experiment.
*P < 0.05, **P < 0.01 vs. the naïve promoter activity.
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Figure 6.
The effect of genotype, g.−66T>C on MATE1 expression levels in human kidney. Expression
of MATE1 in the human kidney was determined by a quantitative real-time RT-PCR. The
expression levels of MATE1 in the T/C or C/C groups were compared with that in the T/T
group. Data shown represent mean ± SD. The P value was calculated using Student’s t test.
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Figure 7.
Schematic of the interaction of the MATE1 promoter with two transcription factors that are
proposed to be involved in the regulation of MATE1. The upper drawing shows the binding of
the transcription factors to the reference allele and the lower drawing shows the binding to g.
−66T>C. The transcription factors, AP-1 and AP-2rep, can bind with the site containing the
variant, g.−66T>C, competitively. AP-1 works as an enhancer of MATE1 transcription while
AP-2rep represses MATE1 transcription. The relative sizes of AP-1 and AP-2rep depict the
relative binding affinity with this region; AP-1 has a higher binding affinity for the g.−66T
allele whereas AP-2rep has a higher binding affinity for the g.−66C allele. Promoter
polymorphisms of MATE1 identified in this study are included in the schematic. Their positions
are based upon the translational start site.
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Table 3
Oligonucleotide primers used in the construction of MATE1 reporter plasmids or AP-2rep plasmid and the
electrophoretic mobility shift analysis
Primers for MATE1 promoter sequencing
  Sense 5’-GGG AGC ATG TTG CTC TAT CC-3’
  Antisense 5’-AGG AGC TTC CAT GTG ACT CG-3’
Primers for MATE1 promoter cloning
  First PCR (−543 to +15)
 Sense 5’-AGT ATG CAA CAC CCT AAC CAG CA-3’
 Antisense 5’-CCT CAG GAG CTT CCA TGT GAC T-3’
  Second PCR (−234 to −12)
 Sense (NheI site)1 5’-CTA GCT AGC GGT GCA GAG AGA GGT GCA A-3’
 Antisense (HindIII site)1 5’-CCC AAG CTT GCT GCG GCC GGG TAG-3’
  Primers for AP-2rep cloning
 Sense (NheI site)1 5’-GCT AGC ATG AAT ATC CAT ATG AAG AGA-3’
 Antisense (KpnI site)1 5’-GGT ACC GCT GGA CAG GTA GCA TTC CTC AC-3’
  Primers for EMSA
 Reference (g.−66T)2 5’-TGC GCG GTA CTC ACT GCC GGC C-3’
 Variant (g.−66C)2 5’-TGC GCG GTA CCC ACT GCC GGC C-3’
 Consensus AP-13 5’-AAG CCT GTG ACT CAG GAC CTG-3’
 Consensus AP-2rep4 5’-CTG GGG CAG TGG GAC TGG CA-3’
1
The restriction endonuclease sites are marked by bold-faced letters.
2
The SNP sites are marked by bold-faced letters.
3,4
The consensus sequences of AP-1 and AP-2rep are marked by bold-faced letters [15,25].
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